<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04862091</url>
  </required_header>
  <id_info>
    <org_study_id>ABTL-PD-01</org_study_id>
    <nct_id>NCT04862091</nct_id>
  </id_info>
  <brief_title>Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer</brief_title>
  <official_title>A Randomized, Open-Label, Multi-Center, Parallel Controlled Study Comparing the Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer After Oral Administration of Abiraterone Acetate Tablets (I) or ZYTIGA®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate whether the efficacy of the abiraterone acetate tablets (I) is comparable to that&#xD;
      of the ZYTIGA®) by comparing the serum testosterone concentrations on Day 9 and/or Day 10&#xD;
      after oral administration of the two formulations in patients with metastatic&#xD;
      castration-resistant prostate cancer (mCRPC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2021</start_date>
  <completion_date type="Anticipated">October 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 25, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Abiraterone Acetate Tablets (I) compared with ZYTIGA®</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum testosterone concentration</measure>
    <time_frame>Day 9/Day 10</time_frame>
    <description>Blood Sample tested for Serum Testosterone Levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSA level</measure>
    <time_frame>Day 28, Day 56, and Day 84</time_frame>
    <description>The serum total PSA level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA-50 response rate</measure>
    <time_frame>Day 28, Day 56, and Day 84</time_frame>
    <description>The percentage of subjects with total serum PSA level decreased by 50% from the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute testosterone concentration</measure>
    <time_frame>Day 9/10, Day 28, Day 56, and Day 84</time_frame>
    <description>The actual measured serum testosterone concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Testosterone inhibition rate</measure>
    <time_frame>Day 9/10, Day 28, Day 56, and Day 84</time_frame>
    <description>The percentage of subjects with a serum testosterone concentration of ≤ 1 ng/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady-state minimum concentration of abiraterone</measure>
    <time_frame>Day 9/10, Day 28, Day 56, and Day 84</time_frame>
    <description>Defined as the plasma concentration of abiraterone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax, ss</measure>
    <time_frame>Day 9</time_frame>
    <description>Defined as the steady-state maximum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-τ</measure>
    <time_frame>Day 9</time_frame>
    <description>Defined as the area under the curve within the dosing interval at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin, ss</measure>
    <time_frame>Day 9</time_frame>
    <description>Defined as the steady-state minimum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cav, ss</measure>
    <time_frame>Day 9</time_frame>
    <description>Defined as the mean blood drug concentration during the dosing interval at steady state</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Metastatic Castration-resistant Prostate Cancer (mCRPC)</condition>
  <arm_group>
    <arm_group_label>Abiraterone Acetate Tablets (I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ZYTIGA®.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone Acetate Tablets (I)</intervention_name>
    <description>Abiraterone Acetate Tablets (I)</description>
    <arm_group_label>Abiraterone Acetate Tablets (I)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZYTIGA®</intervention_name>
    <description>ZYTIGA®</description>
    <arm_group_label>ZYTIGA®.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males, ≥ 18 years old;&#xD;
&#xD;
          2. Histologically or cytologically diagnosed with prostate adenocarcinoma, without&#xD;
             neuroendocrine or small cell characteristics, and having metastatic lesions with&#xD;
             imaging evidence (such as positive bone scan or metastatic lesions on CT/MRI);&#xD;
&#xD;
          3. Serum testosterone level &lt; 50 ng/dL or 1.7 nmol/L at the screening; subjects who have&#xD;
             not undergone bilateral orchidectomy must plan to continue medication throughout the&#xD;
             study to maintain therapy with effective GnRH agonist or antagonist;&#xD;
&#xD;
          4. Progression of prostate cancer as confirmed by diagnostic files, meeting one of the&#xD;
             conditions for disease progression: 1) Biochemistry evidence of recurrence: continuous&#xD;
             3 rises of PSA (taken a minimum of 1 week apart) from a baseline measurement of at&#xD;
             least 2 ng/mL, greater than 50% of the minimum value in 2 rises; 2) Radiographic&#xD;
             progression: a clear evidence of new lesion; 2 or more new bone lesions appearing on&#xD;
             bone scan; CT or MRI showing lesion progression (RECIST 1.1);&#xD;
&#xD;
          5. ECOG performance status score of ≤ 1;&#xD;
&#xD;
          6. Life expectancy of ≥ 6 months;&#xD;
&#xD;
          7. Major organs are functioning well&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of pituitary or adrenal dysfunction;&#xD;
&#xD;
          2. Have used flutamide within 4 weeks before the first dose of study treatment, and&#xD;
             bicalutamide or nilutamide within 6 weeks before the first dose of study treatment;&#xD;
&#xD;
          3. Prior therapy with CYP17 inhibitors (such as abiraterone acetate, ketoconazole,&#xD;
             TAK-700, etc.) or investigational drugs or marketed drugs of new androgen receptor&#xD;
             antagonists (such as enzalutamide, apalutamide, SHR3680, ODM-201, and proxalutamide);&#xD;
&#xD;
          4. Have received 5-reductase inhibitors (such as finasteride and dutasteride), estrogen,&#xD;
             progesterone, any herbal products (such as saw palmetto) that may decrease PSA levels,&#xD;
             and radiotherapy within 4 weeks prior to the start of study medication;&#xD;
&#xD;
          5. Have previously received biotherapy or cytotoxic chemotherapy for mCRPC; patients who&#xD;
             have completed docetaxel treatment for at least 1 year before enrollment can&#xD;
             participate in screening;&#xD;
&#xD;
          6. Prostate cancer with moderate to severe pain symptoms, with a score of &gt; 3 for&#xD;
             Question 3 (the worst pain in the last 24 hours, 0-1 point means asymptomatic, 2-3&#xD;
             points mean mild symptoms) of the Brief Pain Inventory-Short Form (BPI-SF);&#xD;
&#xD;
          7. With contraindications to the use of glucocorticoids, such as uncontrolled persistent&#xD;
             infections or other conditions;&#xD;
&#xD;
          8. Chronic diseases that require systemic corticosteroid therapy (&gt; 10 mg/day prednisone&#xD;
             or equivalent). Patients who have discontinued the administration or reduced the dose&#xD;
             to &lt; 10 mg within 14 days prior to the start of study treatment are eligible;&#xD;
&#xD;
          9. Presence of abdominal fistula, gastrointestinal perforation, abdominal abscess, or&#xD;
             other abnormal gastrointestinal function within 6 months before the first dose of&#xD;
             study treatment, which may affect drug absorption as judged by the investigator;&#xD;
&#xD;
         10. Presence of active heart disease within 6 months prior to the first dose of study&#xD;
             treatment, including: severe/unstable angina, myocardial infarction, symptomatic&#xD;
             congestive heart failure, left ventricular ejection fraction &lt; 50%, and severe&#xD;
             arrhythmia requiring treatment or New York Heart Association (NYHA) Class III-IV heart&#xD;
             failure;&#xD;
&#xD;
         11. Inability to swallow the whole tablet;&#xD;
&#xD;
         12. Other conditions that make the patient unsuitable for the study as judged by the&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuanyuan Huang</last_name>
    <phone>+86 18036618522</phone>
    <email>yuanyuan.huang@hengrui.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dingwei Ye, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 25, 2021</study_first_submitted>
  <study_first_submitted_qc>April 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2021</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

